Absci Corp Reports Q3 2026 Revenue of $0.3M, Net Loss Per Share of -$0.19, Missing Revenue Estimates
Clinical-Stage Biotech Advances ABS-201 Toward December Proof-of-Concept Readout While Cash Position Funds Operations Into Second Half of 2028 Related Stocks: ABSI ,